文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌放疗与NK细胞免疫治疗的演化双 bind 策略

Evolutionary Double-Bind Treatment Using Radiation Therapy and Natural Killer Cell-Based Immunotherapy in Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-09-23

该研究通过体外实验与演化数学模型,首次量化了放疗与自然杀伤(NK)细胞免疫治疗在前列腺癌中形成的演化双 bind 效应。放疗诱导DNA双链断裂并筛选出放疗抵抗细胞,但后者NK细胞配体表达改变,对NK细胞杀伤敏感性增加两倍。模型预测先放疗后NK细胞治疗可实现最佳肿瘤控制,后续实验证实了该预测。

要点

  • 放疗后前列腺癌细胞NK细胞配体改变,对NK细胞杀伤敏感性增加两倍。
  • 放疗单独减缓总体生长但强烈选择放疗抵抗细胞,NK细胞治疗单独抑制抵抗群但敏感细胞存活。
  • 模型预测先放疗后NK细胞治疗达最佳控制,实验证实该预测。

核心结论

  • 放疗与NK细胞免疫治疗在前列腺癌中产生可量化的演化双 bind 效应,该多维策略为个体化治疗设计奠定基础。

研究设计与样本

  • 研究采用体外实验与基于演化的数学模型,使用多种前列腺癌细胞系及同基因放疗抵抗细胞系模型。
  • 引入两群体Lotka-Volterra竞争模型,包含放疗敏感与抵抗群体,建模内在生长率、固定承载容量及种间竞争项。

主要发现

  • 放疗后NK细胞配体改变导致对NK细胞介导杀伤的敏感性增加两倍,并选择性靶向放疗抵抗细胞。
  • 放疗单独减缓总体生长但强烈选择放疗抵抗细胞;NK细胞治疗单独抑制抵抗群体但敏感细胞存活。
  • 模型模拟预测先放疗后NK细胞治疗可实现最佳肿瘤控制,后续实验证实该预测。

临床怎么用

  • 前列腺癌治疗可考虑先放疗后NK细胞免疫治疗的时序组合,以利用演化双 bind 效应抑制治疗抵抗。

局限性

  • 研究基于体外实验与数学模型,尚未在临床环境中验证该演化双 bind 策略的疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Evolution-informed therapies exploit evolutionary consequences of drug resistance to inhibit treatment resistance and prolong time to progression. One strategy, termed an evolutionary double-bind, uses an initial therapy to elicit a specific adaptive response by cancer cells, which is then selectively targeted by a follow-on therapy. Although the concept of an evolutionary double-bind has long been hypothesized in cancer, it has not been measured. Here, to our knowledge, we present the first example of a quantifiable double-bind: radiation therapy (RT) with natural killer (NK) cells. RT induces lethal double-strand DNA breaks, but cancer cells adapt. Although this increases resistance to DNA-damaging agents, it also enhances expression of NK cell ligands creating an obvious choice for a double-bind strategy. METHODS AND MATERIALS: We investigated this potential evolutionary double-bind through in vitro studies and evolution-based mathematical models. Using multiple prostate cancer cell lines, we evaluated surface and soluble NK ligand expression following RT. In vitro competition experiments were performed with an isogenic radiation-resistant cell line model. We introduced a two-population Lotka-Volterra competition model, consisting of radiation-sensitive and radiation-resistant populations modeling intrinsic growth rates with fixed carrying capacity and inter-specific competition terms. RESULTS: Alterations in NK cell ligands resulted in a twofold increase in sensitivity to NK cell-mediated killing with selective targeting of RT-resistant cells. These dynamics were framed mathematically to quantify the double bind. RT alone slowed overall growth but strongly selected for RT-resistant cells. NK cell therapy alone suppressed the RT-resistant population, but with a surviving population of radiation-sensitive cells. Model simulation predicted that optimal tumor control would be achieved through initial RT followed by NK cells. Subsequent experiments confirmed the model prediction. CONCLUSIONS: We conclude that RT and NK cell-based immunotherapy produce an evolutionary double-bind. This multidimensional approach addresses the immediate challenge of treatment resistance and lays the groundwork for the development of personalized treatment regimens tailored to the evolving dynamics of individual tumors. SIGNIFICANCE: Clinical experience demonstrates that prostate cancer has a remarkable capacity to evolve resistance to all currently available treatments resulting in progression and, ultimately, patient death. Resistance mechanisms often come at a fitness cost placing cells in a bind when competing with surrounding cells. A carefully chosen secondary drug can introduce a double-bind targeting the adaptive resistance mechanism. This manuscript provides the first direct experimental evidence quantifying an "evolutionary double-bind' in prostate cancer supporting the combination of DNA-damaging agents and NK cell-based immunotherapy in evolutionarily guided treatment designs. Our work is mathematically novel in that it extends Evolutionary Game Theory models and establishes an experimental-mathematical framework to quantify genuine evolutionary double binds applicable across cancer types and treatment modalities.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Luddy KA, West J, Robertson-Tessi M, et al. Evolutionary Double-Bind Treatment Using Radiation Therapy and Natural Killer Cell-Based Immunotherapy in Prostate Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 40998270. doi:10.1016/j.ijrobp.2025.09.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。